Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Immune Checkpoint Inhibitors Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Immune Checkpoint Inhibitors Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 PD-1/PD-L1
      • 1.3.3 CTLA-4
    • 1.4 Market Segment by Application
      • 1.4.1 Global Immune Checkpoint Inhibitors Market Share by Application (2019-2025)
      • 1.4.2 Lung Cancer
      • 1.4.3 Colorectal Cancer
      • 1.4.4 Breast Cancer
      • 1.4.5 Prostate Cancer
      • 1.4.6 Melanoma
      • 1.4.7 Blood Cancer
      • 1.4.8 Other
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Immune Checkpoint Inhibitors Market Size
      • 2.1.1 Global Immune Checkpoint Inhibitors Revenue 2014-2025
      • 2.1.2 Global Immune Checkpoint Inhibitors Sales 2014-2025
    • 2.2 Immune Checkpoint Inhibitors Growth Rate by Regions
      • 2.2.1 Global Immune Checkpoint Inhibitors Sales by Regions 2014-2019
      • 2.2.2 Global Immune Checkpoint Inhibitors Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Immune Checkpoint Inhibitors Sales by Manufacturers
      • 3.1.1 Immune Checkpoint Inhibitors Sales by Manufacturers 2014-2019
      • 3.1.2 Immune Checkpoint Inhibitors Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Immune Checkpoint Inhibitors Revenue by Manufacturers (2014-2019)
      • 3.2.2 Immune Checkpoint Inhibitors Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Immune Checkpoint Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.3 Immune Checkpoint Inhibitors Price by Manufacturers
    • 3.4 Key Manufacturers Immune Checkpoint Inhibitors Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Immune Checkpoint Inhibitors Market
    • 3.6 Key Manufacturers Immune Checkpoint Inhibitors Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 PD-1/PD-L1 Sales and Revenue (2014-2019)
      • 4.1.2 CTLA-4 Sales and Revenue (2014-2019)
    • 4.2 Global Immune Checkpoint Inhibitors Sales Market Share by Type
    • 4.3 Global Immune Checkpoint Inhibitors Revenue Market Share by Type
    • 4.4 Immune Checkpoint Inhibitors Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Immune Checkpoint Inhibitors Sales by Application

    6 United States

    • 6.1 United States Immune Checkpoint Inhibitors Breakdown Data by Company
    • 6.2 United States Immune Checkpoint Inhibitors Breakdown Data by Type
    • 6.3 United States Immune Checkpoint Inhibitors Breakdown Data by Application

    7 European Union

    • 7.1 European Union Immune Checkpoint Inhibitors Breakdown Data by Company
    • 7.2 European Union Immune Checkpoint Inhibitors Breakdown Data by Type
    • 7.3 European Union Immune Checkpoint Inhibitors Breakdown Data by Application

    8 China

    • 8.1 China Immune Checkpoint Inhibitors Breakdown Data by Company
    • 8.2 China Immune Checkpoint Inhibitors Breakdown Data by Type
    • 8.3 China Immune Checkpoint Inhibitors Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Immune Checkpoint Inhibitors Breakdown Data by Company
    • 9.2 Rest of World Immune Checkpoint Inhibitors Breakdown Data by Type
    • 9.3 Rest of World Immune Checkpoint Inhibitors Breakdown Data by Application
    • 9.4 Rest of World Immune Checkpoint Inhibitors Breakdown Data by Countries
      • 9.4.1 Rest of World Immune Checkpoint Inhibitors Sales by Countries
      • 9.4.2 Rest of World Immune Checkpoint Inhibitors Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Bristol Myer Squibb
      • 10.1.1 Bristol Myer Squibb Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
      • 10.1.4 Immune Checkpoint Inhibitors Product Introduction
      • 10.1.5 Bristol Myer Squibb Recent Development
    • 10.2 AstraZeneca
      • 10.2.1 AstraZeneca Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
      • 10.2.4 Immune Checkpoint Inhibitors Product Introduction
      • 10.2.5 AstraZeneca Recent Development
    • 10.3 Merck & Co.
      • 10.3.1 Merck & Co. Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
      • 10.3.4 Immune Checkpoint Inhibitors Product Introduction
      • 10.3.5 Merck & Co. Recent Development
    • 10.4 Roche / Genentech
      • 10.4.1 Roche / Genentech Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
      • 10.4.4 Immune Checkpoint Inhibitors Product Introduction
      • 10.4.5 Roche / Genentech Recent Development
    • 10.5 Incyte Corporation
      • 10.5.1 Incyte Corporation Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
      • 10.5.4 Immune Checkpoint Inhibitors Product Introduction
      • 10.5.5 Incyte Corporation Recent Development
    • 10.6 NewLink Genetics
      • 10.6.1 NewLink Genetics Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
      • 10.6.4 Immune Checkpoint Inhibitors Product Introduction
      • 10.6.5 NewLink Genetics Recent Development
    • 10.7 ArGEN-X
      • 10.7.1 ArGEN-X Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
      • 10.7.4 Immune Checkpoint Inhibitors Product Introduction
      • 10.7.5 ArGEN-X Recent Development
    • 10.8 Seattle Genetics
      • 10.8.1 Seattle Genetics Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
      • 10.8.4 Immune Checkpoint Inhibitors Product Introduction
      • 10.8.5 Seattle Genetics Recent Development
    • 10.9 Pfizer
      • 10.9.1 Pfizer Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
      • 10.9.4 Immune Checkpoint Inhibitors Product Introduction
      • 10.9.5 Pfizer Recent Development
    • 10.10 MacroGenics
      • 10.10.1 MacroGenics Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
      • 10.10.4 Immune Checkpoint Inhibitors Product Introduction
      • 10.10.5 MacroGenics Recent Development
    • 10.11 Celldex Therapeutics
    • 10.12 CureTech
    • 10.13 Immutep
    • 10.14 Innate Pharma
    • 10.15 Sorrento Therapeutics
    • 10.16 GlaxoSmithKline
    • 10.17 GITR, Inc

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Immune Checkpoint Inhibitors Sales Channels
      • 11.2.2 Immune Checkpoint Inhibitors Distributors
    • 11.3 Immune Checkpoint Inhibitors Customers

    12 Market Forecast

    • 12.1 Global Immune Checkpoint Inhibitors Sales and Revenue Forecast 2019-2025
    • 12.2 Global Immune Checkpoint Inhibitors Sales Forecast by Type
    • 12.3 Global Immune Checkpoint Inhibitors Sales Forecast by Application
    • 12.4 Immune Checkpoint Inhibitors Forecast by Regions
      • 12.4.1 Global Immune Checkpoint Inhibitors Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
      In 2019, the market size of Immune Checkpoint Inhibitors is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Immune Checkpoint Inhibitors.

      This report studies the global market size of Immune Checkpoint Inhibitors, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Immune Checkpoint Inhibitors sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Bristol Myer Squibb
      AstraZeneca
      Merck & Co.
      Roche / Genentech
      Incyte Corporation
      NewLink Genetics
      ArGEN-X
      Seattle Genetics
      Pfizer
      MacroGenics
      Celldex Therapeutics
      CureTech
      Immutep
      Innate Pharma
      Sorrento Therapeutics
      GlaxoSmithKline
      GITR, Inc

      Market Segment by Product Type
      PD-1/PD-L1
      CTLA-4

      Market Segment by Application
      Lung Cancer
      Colorectal Cancer
      Breast Cancer
      Prostate Cancer
      Melanoma
      Blood Cancer
      Other

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Immune Checkpoint Inhibitors status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Immune Checkpoint Inhibitors manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Immune Checkpoint Inhibitors are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now